Study details
Enrolling now
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
Mirador Therapeutics, Inc.
NCT IDNCT07423299ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
19–55
Locations
1 site in CA
About this study
This Phase 1 study is focused on people with healthy volunteers. The primary outcome being measured is Number of Subjects with non-SAEs and SAES.
Based on ClinicalTrials.gov records.
PhasePhase 1
Primary goalNumber of Subjects with non-SAEs and SAES
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of Subjects with non-SAEs and SAES